January 10, 2018 / 1:12 PM / 9 months ago

BRIEF-Atara Biotherapeutics Gets FDA Clearance To Proceed With Multiple Sclerosis study

Jan 10 (Reuters) - Atara Biotherapeutics Inc:

* ATARA BIOTHERAPEUTICS ANNOUNCES FDA CLEARANCE TO PROCEED WITH ENROLLMENT AT U.S. SITES FOR ONGOING GLOBAL PHASE 1 CLINICAL STUDY TO EVALUATE ATA188 IN PATIENTS WITH PROGRESSIVE OR RELAPSING-REMITTING MULTIPLE SCLEROSIS

* ATARA BIOTHERAPEUTICS INC - FIRST RESULTS FROM ATA188 PHASE 1 STUDY IN PATIENTS WITH PROGRESSIVE MS IN FIRST HALF OF 2019 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below